X

Trial Profile

A phase I trial and pharmacokinetic study of trabectedin (Yondelis, ET-743 [ecteinascidin]) in children and adolescents with relapsed or refractory solid tumors.

Status: Completed

Phase of Trial: Phase I

Latest Information Update: 17 Sep 2021

Price : $35 ^*

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Trabectedin (Primary) ; Filgrastim; Pegfilgrastim
Indications Brain cancer; Ewing's sarcoma; Germ cell and embryonal neoplasms; Germ cell cancer; Hepatic tumours; Neuroblastoma; Osteosarcoma; Soft tissue sarcoma; Solid tumours; Wilms' tumour
Focus Adverse reactions; Pharmacogenomic

Most Recent Events

05 Apr 2012 Additional lead trial investigator identified as reported by ClinicalTrials.gov.
05 Apr 2012 Additional lead trial investigator identified as reported by ClinicalTrials.gov.
15 Oct 2011 Actual end date (October 2011) added as reported by ClinicalTrials.gov.

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com